Low density lipoproteins mediated nanoplatforms for cancer targeting
Source abstract
Abstract
Chemotherapy is a foremost remedial approach for the treatment of localized and metastasized tumors. In order to explore new treatment modalities for cancer, it is important to identify qualitative or quanti- tative differences in metabolic processes between normal and malignant cells. One such difference may be that of increased receptor-mediated cellular uptake of low density lipoproteins (LDLs) by cancer cells. Lipoproteins in general and specifically LDL are ideal candidates for loading and delivering cancer therapeutic and diagnostic agents due to their biocompatibility. By mimicking the endogenous shape and structure of lipoproteins, the reconstituted lipoproteins can remain in circulation for an extended period of time, while largely evading the reticuloendothelial cells in the body's defenses. In this account, we review the field of low density inspired nanoparticles in relation to the delivery of cancer imaging and therapeutic agents. LDL has instinctive cancer targeting potential and has been used to incorporate various lipophillic molecules to transport them to tumors. Nature's method of rerouting LDL provides a strategy to extend the cancer targeting potential of lipoproteins far off its constricted purview. In this review, we have discussed the various aspects of LDL including its role in cancer imaging and chemotherapy in retrospect and prospect and current efforts aimed to further improve the delivery efficacy of LDL-drug complexes with reduced chances of drug resistance leading to optimal drug delivery. This review provides a strong support for the concept of using LDL as a drug carrier.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cancer, Lipids, and Metabolism · Cholesterol and Lipid Metabolism · Peroxisome Proliferator-Activated Receptors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Anderson RGW, Brown MS, Goldstein JL (1977) The role of the coated endocytotic vesicle in the uptake of receptor bound low density lipoproteins in the human fibroblast cell. Cell 10:351–36410.1016/0092-8674(77)90022-8 ↗
2. Angelin B, Raviola CA, Innerarity TL, Mahley RW (1983) Rapid regulation of apolipoprotein B/E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids. J Clin Invest 71:816–83110.1172/JCI110835 ↗
3. Arias-Moreno X, Velazquez-Campoy A, Rodriguez JC, Pocov M, Sancho J (2008) Mechanism of low density lipoprotein (LDL) release in the endosome: implications of the stability and Ca2+ affinity of the fifth binding module of the LDL receptor. J Biol Chem 283:22670–2267910.1074/jbc.M802153200 ↗
4. Bachor R, Shea CR, Gillies R, Hasan T (1991) Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres. Proc Natl Acad Sci USA 88:1580–158410.1073/pnas.88.4.1580 ↗
5. Bertato MP, Oliveira CP, Wajchenberg BL, Lerario AC, Maranhão RC (2012) Plasma kinetics of an LDL-like nanoemulsion and lipid transfer to HDL in subjects with glucose intolerance. Clinics (Sao Paulo) 67:347–35310.6061/clinics/2012(04)08 ↗
6. Bi WX, Xu SD, Zhang PH, Kong P (2000) Antitumoral activity of low density lipoprotein aclacinomycin complex in mice bearing H22 tumor. World J Gastroenterol 6:140–14210.3748/wjg.v6.i1.140 ↗
7. Bien CM, Espenshade PJ (2010) Proteins in fungi: hypoxic transcription factors linked to pathogenesis. Eukaryot Cell 9:352–35910.1128/EC.00358-09 ↗
8. Bijsterbosch MK, Van Berkel TJC (1990) Uptake of lactosylated low density lipoprotein by galactose-specific receptors in rat liver. Biochem J 270:233–23910.1042/bj2700233 ↗
9. Bildstein L, Dubernet C, Couvreur P (2011) Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev 63:3–2310.1016/j.addr.2010.12.005 ↗
10. Bilheimer DW, Grundy SM, Brown MS, Goldstein JS (1983) Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80:4124–412810.1073/pnas.80.13.4124 ↗
11. Bozoky Z, Balogh L, Mathe D, Fulop L, Bertok L, Janoki GA (2004) Preparation and investigation of 99m technetium labeled low density lipoproteins in rabbits with experimentally induced hypercholesterolemia. Eur Biophys J 33:140–14510.1007/s00249-003-0334-7 ↗
12. Brown MS, Goldstein JL (1974) Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA 71:788–79210.1073/pnas.71.3.788 ↗
13. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232:34–4710.1126/science.3513311 ↗
14. Brown MS, Goldstein JL (1994) A receptor-mediated pathway for cholesterol binding of anthracycline derivatives to human serum lipoproteins. Anticancer Res 14:2353–2355
15. Brown MS, Goldstein JL (2009) Cholesterol feedback: from Schoenheimer’s bottle to Scap’s Meladl. J Lipid Res 50:S15–S2710.1194/jlr.R800054-JLR200 ↗
16. Brown MS, Brannan PG, Bohmfalk HA, Brunschede GY, Dana SE, Helgeson J, Goldstein JL (1975) Use of mutant fibroblasts in the analysis of the regulation of cholesterol metabolism in human cells. J Cell Physiol 85:425–43610.1002/jcp.1040850409 ↗
17. Callahan DE, Forte TM, Afzal SMJ, Deen DF, Kahl SB, Bjornstad KA, Bauer WF, Blakely EA (1991) Boronated protoporphyrin (BOPP): localization in lysosomes of the human glioma cell line SF-767 with uptake modulated by lipoprotein levels. Int J Radiat Oncol Biol Phys 3:488–495
18. Caruso MG, Osella AR, Notarnicola M, Berloco P, Leo S, Bonfiglio C, Di Leo A (1998) Prognostic value of low density lipoprotein receptor expression in colorectal carcinoma. Oncol Rep 5:927–930
19. Caruso MG, Notarnicola M, Cavallini A (2001) Low density lipoprotein receptor and mRNA expression in human colorectal cancer. Anticancer Res 21:429–433
20. Caruso MG, Messa C, Orlando A, Attoma BD, Notarnicola M (2008) Early induction of LDL receptor gene expression by genistein in DLD-1 colon cancer cell line. Fitoterapia 79:524–52810.1016/j.fitote.2008.05.003 ↗
21. Cerda SR, Wilkinson J 4th, Broitman SA (1995) Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Lipids 30:1083–109210.1007/BF02536608 ↗
22. Chao FC, Efron B, Wolf P (1975) The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy. Cancer 35:1223–122910.1002/1097-0142(197504)35:4<1223::AID-CNCR2820350429>3.0.CO;2-T ↗
23. Chapman MJ (1980) Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 21:789–85310.1016/S0022-2275(20)34780-5 ↗
24. Chappell DA, Fry GL, Waknitz MA, Berns JJ (1991) Ligand size as a determinant for catabolism by the low density lipoprotein (LDL) receptor pathway: a lattice model for LDL binding. J Biol Chem 266:19296–1930210.1016/S0021-9258(18)54997-8 ↗
25. Chassany O, Urien S, Claudepierre P, Bastian G, Tillement JP (1994) Binding of anthracyclines derivatives to human serum lipoproteins. Anticancer Res 14:2353–2355
26. Chen Y, Hughes-Fulford M (2001) Human prostate cancer cells lack feedback regulation of low density lipoprotein receptor and its regulator, SREBP2. Int J Cancer 91:41–4510.1002/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2 ↗
27. Chu AC, Tsang SY, Lo EH, Fung KP (2001) Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci 70:591–60110.1016/S0024-3205(01)01441-2 ↗
28. Chung NS, Wasan KM (2004) Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 56:1315–133410.1016/j.addr.2003.12.003 ↗
29. Ciftci K, Trovitch P (2003) Current approaches in the treatment of melanoma-II: immuno and gene therapy. Turk J Cancer 33:127–136
30. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37:161–16510.1038/ng1509 ↗
31. Corbin IR, Li H, Chen J, Lund-Katz S, Zhou R, Glickson JD, Zheng G (2006) Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8:488–49810.1593/neo.05835 ↗
32. Corbin IR, Chen J, Cao W, Li H, Lund-Katz S, Zhou R, Glickson JD, Zheng G (2007) Enhanced cancer-targeted delivery using engineered high density lipoprotein based nanocarriers. J Biomed Nanotechnol 3:367–37610.1166/jbn.2007.053 ↗
33. Crich SG, Lanzardo S, Alberti D, Belfiore S, Ciampa A, Giovenzana GB, Lovazzano C, Pagliarin R, Aime S (2007) Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia 9:1046–105610.1593/neo.07682 ↗
34. Davis CG, Elhammer A, Russell DW, Schneider WJ, Kornfeld S, Brown MS, Goldstein JL (1986) Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts. J Biol Chem 261:2828–283810.1016/S0021-9258(17)35862-3 ↗
35. Davis CG, van Driel IR, Russell DW, Brown MS, Goldstein JL (1987) The low density lipoprotein receptor identification of amino acids in cytoplasmic domain required for rapid endocytosis. J Biol Chem 262:407510.1016/S0021-9258(18)61313-4 ↗
36. De Smidt PC, Van Berkel TJC (1990) Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res 50:7476–7482
37. Decker EA (1995) The role of phenolics, conjugated linoleic acid, carnosine, and pyrroloquinoline quinone as nonessential dietary antioxidants. Nutr Rev 53:49–5810.1111/j.1753-4887.1995.tb01502.x ↗
38. Deforge LE, Degalan MR, Ruyan MK, Newton RS, Raymond E (1992) Comparison of methods for incorporating a radioiodinated residualizing cholesteryl ester analog into low density lipoprotein. Int J Radiat Appl Instrum B 19:115–18210.1016/0883-2897(92)90139-P ↗
39. Dehouck B, Dehouck MP, Fruchart JC, Cacchelli R (1994) Upregulation of low density lipoprotein receptor at blood brain barrier: intercommunication between brain capillary endothelial cells and astrocytes. J Cell Biol 126:465–47310.1083/jcb.126.2.465 ↗
40. Dietschy JM, Woollett LA, Spady DK (1993) The interaction of dietary cholesterol and specific fatty acids in the regulation of LDL receptor activity and plasma LDL-cholesterol concentrations. Ann N Y Acad Sci 676:11–2610.1111/j.1749-6632.1993.tb38722.x ↗
41. Dougherty TJ (1989) Photodynamic therapy—new approaches. Semin Surg Oncol 5:6–1610.1002/ssu.2980050104 ↗
42. Eisenberg S, Windmueller HG, Levy RI (1973) Metabolic fate of rat and human lipoprotein apolipoproteins in the rat. J Lipid Res 14:446–45810.1016/S0022-2275(20)36878-4 ↗
43. Eley JG, Halbert GW, Florence AT (1990a) Incorporation of prednimustine into low density lipoprotein: activity against P388 cells in tissue culture. Int J Pharm 65:219–22410.1016/0378-5173(90)90146-U ↗
44. Eley JG, Halbert GW, Florence AT (1990b) The incorporation of estramustine into low density lipoprotein and its activity in tissue culture. Int J Pharm 63:121–12710.1016/0378-5173(90)90161-V ↗
45. Fass D, Blacklow S, Kim PS, Berger JM (1997) Molecular basis of familial hypercholesterolemia from structure of LDL receptor module. Nature 388:691–69310.1038/41798 ↗
46. Favre G (1992) Targeting of tumor cells by low density lipoproteins: principle and use of ellipticine derivatives. C R Seances Soc Biol Fil 186:73–87
47. Filipovic I, Buddecke E (1986) Calcium channel blockers stimulate LDL receptor synthesis in human skin fibroblasts. Biochem Biophys Res Commun 136:845–85010.1016/0006-291X(86)90409-2 ↗
48. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP (2009) Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 35:175–18410.1016/j.ctrv.2008.09.007 ↗
49. Firestone RA (1994) Low density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 5:105–11310.1021/bc00026a002 ↗
50. Firestone RA, Pisano JM, Falck JR (1984) Selective delivery of cytotoxic compounds to cells by the LDL pathway. J Med Chem 27:1037–104310.1021/jm00374a017 ↗
51. Folsch H, Ohno H, Bonifacino JS, Mellman I (1999) A novel clathrin adaptor complex mediates basolateral targeting in polarized epithelial cells. Cell 99:189–19810.1016/S0092-8674(00)81650-5 ↗
52. Fox PL, DiCorleto PE (1986) Modified low density lipoproteins suppress production of a platelet-derived growth factor-like protein by cultured endothelial cells. Proc Natl Acad Sci USA 83:4774–477810.1073/pnas.83.13.4774 ↗
53. Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ, Simpson ER (1981) LDL as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol 139:877–88510.1016/0002-9378(81)90952-2 ↗
54. Garand C, Guay D, Sereduk C, Chow D, Tsofack SP, Langlois M, Perreault E, Yin HH, Lebel M (2011) An integrative approach to identity YB-1 interacting proteins required for cisplatin resistance in MCF and MDA-MB-231 breast cancer cells. Cancer Sci 102:1410–141710.1111/j.1349-7006.2011.01948.x ↗
55. Geninatti-Crich S, Alberti D, Szabo I, Deagostino A, Toppino A, Barge A, Ballarini F, Bortolussi S, Bruschi P, Protti N, Stella S, Altieri S, Venturello P, Aime S (2011) MRI-guided neutron capture therapy by use of a dual gadolinium/boron agent targeted at tumour cells through upregulated low-density lipoprotein transporters. Chemistry 17:8479–848610.1002/chem.201003741 ↗
56. Glickson JD (2005) Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 49:17757–17762
57. Goldstein JL, Brown MS (1973) Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity associated with overproduction of cholesterol (cholesterol synthesis/hyperlipidemia/low density lipoproteins/enzyme regulation/coronary heart disease). Proc Natl Acad Sci USA 70:2804–280810.1073/pnas.70.10.2804 ↗
58. Goldstein JL, Brown MS (2001) Molecular medicine. The cholesterol quartet. Science 292:1310–131210.1126/science.1061815 ↗
59. Goldstein JL, Brown MS (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29:431–43810.1161/ATVBAHA.108.179564 ↗
60. Goto D, Okimoto T, Ono M, Shimotsu H, Abe K, Tsujita Y, Kuwano M (1997) Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts. Arteioscler Thromb Vasc Biol 17:2707–271210.1161/01.ATV.17.11.2707 ↗
61. Gregoriades G, Wills EJ, Swain CP, Tavill AS (1974) Drug carrier potential of liposomes in cancer chemotherapy. Lancet 1313–131610.1016/S0140-6736(74)90682-5 ↗
62. Grove RI, Mazzucco CE, Radika SF, Shoyab M, Kiener PA (1991) Oncostatin M up-regulates low density lipoprotein receptors in HepG2 cells by a novel mechanism. J Biol Chem 266:18194–1819910.1016/S0021-9258(18)55254-6 ↗
63. Gueddari N, Favre G, Hachem H, Marek E, Gaillard FL, Soula G (1993) Evidence for up-regulated LDLR in human lung adenocarcinoma cell line A549. Biochimie 75:811–81910.1016/0300-9084(93)90132-C ↗
64. Habenicht AJ, Salbach P, Goerig M, Zeh W, Janssen-Timmen U, Blattner C (1990) The LDL receptor pathway delivers arachidonic acid for eicosanoid formation in cells stimulated by platelet-derived growth factor. Nature (Lond) 345:634–63610.1038/345634a0 ↗
65. Hamanaka R, Kohno K, Seguchi T, Okamura K, Morimoto A, Ono M (1992) Transcription factor SP-1 by tumor necrosis factor in human microvascular endothelial cells. J Biol Chem 267:13160–1316510.1016/S0021-9258(18)42187-4 ↗
66. Hamblin MR, Newman EL (1994) Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins. J Photochem Photobiol, B 26:147–15710.1016/1011-1344(94)07036-9 ↗
67. Handley DA, Arbeeny CM, Chien S (1980) Colloidal gold–low density lipoprotein conjugates as membrane receptor probes. Circulation 62:211
68. Handley DA, Arbeeny CM, Eder HA, Chien S (1981) Hepatic binding and internalization of low density lipoprotein–gold conjugates in rats treated with 17α-ethinylestradiol. J Cell Biol 90:778–78710.1083/jcb.90.3.778 ↗
69. Harada K, Shimano H, Kawakami M, Ishibashi S, Gotoda T, Mori N, Takaku F, Yamada N (1990) Effect of tumor necrosis factor/cachectin on the activity of the low density lipoprotein receptor on human skin fibroblasts. Biochem Biophys Res Commun 172:1022–102710.1016/0006-291X(90)91548-7 ↗
70. Hasan T (1992) Photosensitizer delivery mediated by macromolecular carrier systems. In: Henderson B, Dougherty T (eds) Photodynamic therapy: basic principles and clinical applications. Marcel Dekker, New York, pp 187–200
71. Hasan T, Parrish JA (1996) Photodynamic therapy of cancer. In: Holland JF (ed) Cancer medicine, 4th edn. Williams and Wilkins, Baltimore, pp 739–751
72. Hay RV, Fleming RM, Ryan JW, Williams KA, Stark VJ, Stark VJ, Lathrop KA, Harper PV (1991) Nuclear imaging analysis of human low-density lipoprotein biodistribution in rabbits and monkeys. J Nucl Med 32:1239–1245
73. He G, Gupta S, Yi M, Michaely P, Hobbs HH, Cohen JC (2002) ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. J Biol Chem 277:44044–4404910.1074/jbc.M208539200 ↗
74. Henriksson P, Ericsson S, Stege R, Ericsson M, Rudling M, Berglund L, Angelin B (1989) Hypercholesterolemia and increased elimination of low density lipoprotein receptor activity in metastatic cancer of the prostate. Lancet 2:1178–118010.1016/S0140-6736(89)91790-X ↗
75. Ho YK, Smith RG, Brown MS, Goldstein JL (1978) Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52:1099–111410.1182/blood.V52.6.1099.1099 ↗
76. Ho YK, Smith GR, Brown MS, Goldstein JL (1979) Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 56:1099–1114
77. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–113110.1172/JCI0215593 ↗
78. Huang S, Henry L, Ho YK, Pownall HJ, Rudenko G (2010) Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J Lipid Res 51:297–30810.1194/jlr.M000422 ↗
79. Hynds SA, Welsh J, Stewart JM, Jack A, Soukop M, Mcardle CS, Calman KC, Packard CJ, Stephard J (1984) Low density lipoprotein metabolism in mice with soft tissue tumors. Biochim Biophys Acta 795:589–59510.1016/0005-2760(84)90189-9 ↗
80. Innerarity TL, Friedlander EJ, Rall SC Jr, Weisgraber KH, Mahley RW (1983) The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J Biol Chem 258:12341–1234710.1016/S0021-9258(17)44180-9 ↗
81. Ip C, Dong Y, Ip MM, Banni S, Carta G, Angioni E, Murru E, Spada S, Melis MP, Saebo A (2002) Conjugated linoleic acid isomers and mammary cancer prevention. Nutr Cancer 43:52–5810.1207/S15327914NC431_6 ↗
82. Jack RW, Michelle BM, Liang JW (1994) Low density lipoprotein as a transporter of dolichol intermediates in mammalian circulation. Biochem J 297:321–32510.1042/bj2970321 ↗
83. Jasanda F, Urizzi P, Souchard JP, Le Gaillard F, Favre G, Nepveu F (1996) Indium-111 labeling of low density lipoproteins with the DTPA-bis (stearylamide): evaluation as a potential radiopharmaceutical for tumor localization. Bioconjug Chem 7:2–81
84. Jeon H, Blacklow SC (2005) Structure and physiologic function of the low-density lipoprotein receptor. Annu Rev Biochem 74:535–56210.1146/annurev.biochem.74.082803.133354 ↗
85. Jeon H, Meng W, Takagi J, Eck MJ, Springer TA, Blacklow SC (2001) Implications of familial hypercholesterolemia from the structure of the LDL receptor YWTD EGF domain pair. Nat Struct Biol 8:499–50410.1038/88556 ↗
86. Jiang FN, Allison B, Liu D, Levy JG (1991) Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems. J Control Release 19:41–5810.1016/0168-3659(92)90064-X ↗
87. Jonnalagadda SC, Cruz JS, Connell RJ, Scottc PM, Mereddy VR (2009) Synthesis of α-carboranyl-α-acyloxy-amides as potential BNCT agents. Tetrahedron Lett 50:4314–431710.1016/j.tetlet.2009.05.026 ↗
88. Jori G (1989) In vivo transport and pharmacokinetic behaviour of tumour photosensitizers. In: Photosensitizing compounds: their chemistry, biology and clinical use, Ciba foundation symposium 146, Wiley, Chichester
89. Jori G (1990) Factors controlling the selectivity and efficiency of tumour damage of photodynamic therapy. Lasers Med Sci 5:115–12010.1007/BF02031372 ↗
90. Jori G (1991) Low-density lipoproteins-liposome delivery systems for tumor photosensitizers in vivo. In: Henderson BW, Dougherty TJ (eds) Photodynamic therapy. Marcel Dekker, New York, pp 173–186
91. Jori G, Reddi E (1993) Strategies for tumour targeting by photodynamic sensitizers. In: Kessel D (ed) Photodynamic therapy of neoplastic disease. CRC Press, Boca Raton, pp 117–130
92. Jori G, Beltramini M, Reddi E, Pagnan A, Tomio L, Tsanov T (1984) Evidence for a major role of plasma lipoproteins as haematoporphyrin carriers in vivo. Cancer Lett 24:291–29710.1016/0304-3835(84)90025-9 ↗
93. Jung-Testas I, Weintraub H, Dupuis D, Eychenne B, Baulieu DE, Robel P (1992) Low density lipoprotein-receptors in primary cultures of rat glial cells. J Steroid Biochem Mol Biol 42:597–60510.1016/0960-0760(92)90450-W ↗
94. Kader A, Pater A (2002) Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release 80:29–4410.1016/S0168-3659(01)00536-3 ↗
95. Kader A, Davis PJ, Kara M, Liu H (1998) Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J Control Release 55:231–24310.1016/S0168-3659(98)00052-2 ↗
96. Kahl SB, Wainschel LA, Pate DW, Callaway JC, Hiltunen J (1993) In vitro and in vivo studies with boronated low density lipoproteins for neutron capture. In: Autrinen L, Kallio M (eds) Proceedings of clinical BNCT workshop, Helsinki, pp 105–109
97. Kerr DJ, Hynds SA, Shepherd J, Packard CJ, Kaye SB (1988) Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers. Biochem Pharmacol 37:3981–398610.1016/0006-2952(88)90083-4 ↗
98. Khan IU, Beck-Sickinger AG (2008) Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 8:186–19910.2174/187152008783497046 ↗
99. Kibbey RG, Rizo J, Gierasch LM, Anderson RG (1998) The LDL receptor clustering motif interacts with the clathrin terminal domain in a reverse turn conformation. J Cell Biol 142:59–6710.1083/jcb.142.1.59 ↗
100. Kita T, Brown MS, Watanabe Y, Goldstein JL (1981) Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA 78:2268–227210.1073/pnas.78.4.2268 ↗